Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study
- PMID: 18178368
- DOI: 10.1016/j.jpainsymman.2007.04.018
Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study
Abstract
The aim of this prospective cohort study was to confirm the safety of intravenous morphine (IV-M) used in doses proportional to the basal opioid regimen for the management of breakthrough pain and to record the nurse compliance on regularly recording data regarding breakthrough pain treated by IV-M. Over a one-year period, 99 patients received IV-M for breakthrough pain during 116 admissions. The IV-M dose was 1/5 of the oral daily dose, converted using an equianalgesic ratio of 1/3 (IV/oral). For each episode, nurses were instructed to routinely collect changes in pain intensity and emerging problems when pain became severe (T0), and to reassess the patient 15minutes after IV-M injection (T15). Nurses were unaware of the aim of the study and just followed department policy. In total, 945 breakthrough events treated by IV-M were recorded and the mean number of events per patient per admission was eight (95% confidence interval (CI) 6.9-9.5). The mean dose of IV-M was 12mg (95% CI 9-14mg). In the 469 events (49.6%) with a complete assessment, a decrease in pain of more than 33% and 50% was observed in 287 (61.2%) and 115 (24.5%) breakthrough events, respectively. The mean pain intensity decreased from 7.2 (T0) to 2.7 (T15). In eight episodes, no changes in pain intensity were observed and a further dose of IV-M was given. The remaining patients did not require further interventions. No clinical events requiring medical intervention were recorded. In this confirmatory study, IV-M was administered for the management of breakthrough pain in doses proportional to the basal opioid regimen to all patients, including older patients and those requiring relatively large doses. This did not result in life-threatening adverse effects in a large number of patients and was effective in most cases. The role of nurses is of paramount importance in monitoring and collecting data and gathering information for audit purposes on the unit.
Similar articles
-
Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose.J Pain Symptom Manage. 2004 Apr;27(4):352-9. doi: 10.1016/j.jpainsymman.2003.09.006. J Pain Symptom Manage. 2004. PMID: 15050663
-
Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.J Pain Symptom Manage. 2006 Aug;32(2):175-9. doi: 10.1016/j.jpainsymman.2006.01.013. J Pain Symptom Manage. 2006. PMID: 16877185 Clinical Trial.
-
The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen.Clin J Pain. 2010 May;26(4):306-9. doi: 10.1097/AJP.0b013e3181c4458a. Clin J Pain. 2010. PMID: 20393265 Clinical Trial.
-
Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23. Pain Pract. 2008. PMID: 18503626
-
Lack of opioid administration in older hip fracture patients (CE).Geriatr Nurs. 2003 Nov-Dec;24(6):353-60. doi: 10.1016/j.gerinurse.2003.09.006. Geriatr Nurs. 2003. PMID: 14694324 Review.
Cited by
-
Once again... breakthrough cancer pain: an updated overview.J Anesth Analg Crit Care. 2023 Jul 21;3(1):23. doi: 10.1186/s44158-023-00101-x. J Anesth Analg Crit Care. 2023. PMID: 37480136 Free PMC article. Review.
-
Pain care for patients with epidermolysis bullosa: best care practice guidelines.BMC Med. 2014 Oct 9;12:178. doi: 10.1186/s12916-014-0178-2. BMC Med. 2014. PMID: 25603875 Free PMC article.
-
The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting.Support Care Cancer. 2013 Aug;21(8):2335-9. doi: 10.1007/s00520-013-1799-2. Epub 2013 Apr 7. Support Care Cancer. 2013. PMID: 23564072
-
The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study.Support Care Cancer. 2011 Mar;19(3):435-8. doi: 10.1007/s00520-010-1015-6. Epub 2010 Sep 30. Support Care Cancer. 2011. PMID: 20882391 Clinical Trial.
-
The Endless Question of Opioid Doses for Breakthrough Pain.Oncologist. 2020 Jul;25(7):e1134-e1135. doi: 10.1634/theoncologist.2020-0312. Epub 2020 Jun 4. Oncologist. 2020. PMID: 32400063 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical